The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Somnath Chatterjee
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Somnath Chatterjee, Promoter, Chairman and Joint Managing Director of Suraksha Diagnostic Ltd, bought 8,190 equity shares through an open market purchase on 12 August 2025. This nudged his holding from 26,22,343 shares (5.034%) to 26,30,533 shares (5.051%) of the company. The transaction is a routine SEBI Regulation 29(2) disclosure, indicating a small incremental acquisition rather than a major stake change. The total paid-up equity capital remained unchanged at 5,20,80,758 shares of ₹2 each.
The acquisition is very small (just 0.016% increase in promoter's stake) and signals continued promoter confidence, though it is unlikely to materially move the stock price on its own.